Toposar™ Etoposide Injection,
USP
| General
Information: Etoposide Injection is typically utilized, in combination with other chemotherapeutic agents, in the treatment of refactory testicular tumors and in combination with other chemotherapeutic agents as a first-line treatment for small cell lung cancer. |
| |
| Manufacturer |
Products |
Size |
NDC |
PI |
MSDS |
| TEVA |
Toposar INJ |
100 mg/ 5 mL |
00703-5653-01 |
PI |
MSDS |
|
|
|
500 mg/ 25 mL |
00703-5656-01 |
PI |
MSDS |
|
|
|
1 gm/ 50 mL |
00703-5657-01 |
PI |
MSDS |
|
Accord |
Etoposide INJ |
100mg/5mL |
16729-0114-31 |
PI |
MSDS |
|
| |
| Clinical
Data: For any questions
or for further information
related to Toposar™ Etoposide Injection,
USP, clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and/or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |